The addition of rituximab to anthracycline‐based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B‐cell lymphoma

Some case reports and a Japanese series suggest benefit from the use of rituximab in patients with intravascular large B‐cell lymphoma (IVL). Rituximab efficacy was evaluated in Western patients with IVL, comparing outcome of 10 patients treated with rituximab + chemotherapy (R‐CT) and of 20 patients treated with chemotherapy alone (CT). There were no significant differences in patients’ characteristics between the two subgroups. The addition of rituximab was associated with improved complete remission rate (90% vs. 50%; P = 0·04), event‐free survival (3‐year: 89% vs. 35%; P = 0·003) and overall survival (3‐year: 89% vs. 38%; P = 0·01). In conclusion, rituximab may substantially change the dismal prognosis of IVL.

[1]  T. Naoe,et al.  Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Campo,et al.  Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Ganguly.  Acute intracerebral hemorrhage in intravascular lymphoma: a serious infusion related adverse event of rituximab. , 2007, American journal of clinical oncology.

[4]  E. Campo,et al.  Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. , 2007, Haematologica.

[5]  A. López-Guillermo,et al.  Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’ 1 , 2004, British journal of haematology.

[6]  A. López-Guillermo,et al.  Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Masatoshi Watanabe,et al.  Intravascular large B‐cell lymphoma presenting with mass lesions in the central nervous system: A report of five cases , 2004, Pathology international.

[8]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[9]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Nakamura,et al.  An Asian variant of intravascular lymphomatosis: an updated review of malignant histiocytosis-like B-cell lymphoma. , 1999, Leukemia & lymphoma.

[11]  島田 和之.  Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan , 2009 .

[12]  B. Ko,et al.  Severe pulmonary complications after initial treatment with Rituximab for the Asian-variant of intravascular lymphoma. , 2007, Haematologica.

[13]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.